HK1053975A1 - Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan - Google Patents
Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecanInfo
- Publication number
- HK1053975A1 HK1053975A1 HK03106060A HK03106060A HK1053975A1 HK 1053975 A1 HK1053975 A1 HK 1053975A1 HK 03106060 A HK03106060 A HK 03106060A HK 03106060 A HK03106060 A HK 03106060A HK 1053975 A1 HK1053975 A1 HK 1053975A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- thalidomide
- irinotecan
- treatment
- colorectal cancer
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20414200P | 2000-05-15 | 2000-05-15 | |
PCT/US2001/015326 WO2001087306A2 (en) | 2000-05-15 | 2001-05-10 | Compositions and methods for the treatment of colorectal cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1053975A1 true HK1053975A1 (en) | 2003-11-14 |
Family
ID=22756801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03106060A HK1053975A1 (en) | 2000-05-15 | 2003-08-23 | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
Country Status (13)
Country | Link |
---|---|
US (2) | US6914067B2 (da) |
EP (1) | EP1286671B1 (da) |
JP (1) | JP4679028B2 (da) |
AT (1) | ATE322265T1 (da) |
AU (2) | AU2001261473B2 (da) |
CA (1) | CA2408710C (da) |
DE (1) | DE60118547T2 (da) |
DK (1) | DK1286671T3 (da) |
ES (1) | ES2261415T3 (da) |
HK (1) | HK1053975A1 (da) |
NZ (1) | NZ522766A (da) |
PT (1) | PT1286671E (da) |
WO (1) | WO2001087306A2 (da) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6881420B2 (en) * | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
WO2003013536A2 (en) * | 2001-07-23 | 2003-02-20 | Epidauros Biotechnologie Ag | Methods for treatment of cancer using irinotecan based on ugt1a1 |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US9006267B2 (en) * | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US6987012B2 (en) * | 2003-06-11 | 2006-01-17 | Ultra Biotech Limited | Biological compositions and methods for treatment of colorectal cancer |
EP1684758A4 (en) * | 2003-11-06 | 2009-02-18 | Celgene Corp | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
EP1746976B1 (en) | 2004-05-03 | 2017-01-11 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery |
CA2503099A1 (en) * | 2005-04-18 | 2006-10-18 | Kabushiki Kaisha Yakult Honsha | Pharmaceutical compositions containing camptothecins |
JP2008540585A (ja) * | 2005-05-19 | 2008-11-20 | プロメティック・バイオサイエンスィズ・インコーポレーテッド | 転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法 |
JP2009509171A (ja) * | 2005-09-21 | 2009-03-05 | シーシーシー ダイアグノスティックス, エルエルシー | 個別化抗癌化学療法(pac)のための包括的な診断試験 |
US20070219825A1 (en) * | 2005-11-23 | 2007-09-20 | Maetzold Derek J | Method of managing and reducing side effects associated with exposure to a drug |
US7723301B2 (en) * | 2007-08-29 | 2010-05-25 | The Board Of Trustees Of The University Of Arkansas | Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
US10098813B2 (en) | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
MX2018001802A (es) | 2015-08-21 | 2018-05-16 | Ipsen Biopharm Ltd | Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino. |
EP3362049A1 (en) | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
IL261038B2 (en) | 2016-02-09 | 2024-06-01 | Sun Pharmaceutical Ind Ltd | perfusion system |
KR20190077441A (ko) | 2016-11-02 | 2019-07-03 | 입센 바이오팜 리미티드 | 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
EP4017879A2 (en) * | 2019-08-19 | 2022-06-29 | Merus N.V. | Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
BR9807271A (pt) * | 1997-02-27 | 2000-05-23 | Pharmacia & Upjohn Spa | Tamoxifeno como terapia para reduzir diarréia induzida por cloridrato de irinotecano |
-
2001
- 2001-05-10 NZ NZ522766A patent/NZ522766A/en not_active IP Right Cessation
- 2001-05-10 AU AU2001261473A patent/AU2001261473B2/en not_active Ceased
- 2001-05-10 DK DK01935372T patent/DK1286671T3/da active
- 2001-05-10 AU AU6147301A patent/AU6147301A/xx active Pending
- 2001-05-10 DE DE60118547T patent/DE60118547T2/de not_active Expired - Lifetime
- 2001-05-10 JP JP2001583774A patent/JP4679028B2/ja not_active Expired - Fee Related
- 2001-05-10 WO PCT/US2001/015326 patent/WO2001087306A2/en active IP Right Grant
- 2001-05-10 EP EP01935372A patent/EP1286671B1/en not_active Expired - Lifetime
- 2001-05-10 AT AT01935372T patent/ATE322265T1/de active
- 2001-05-10 ES ES01935372T patent/ES2261415T3/es not_active Expired - Lifetime
- 2001-05-10 PT PT01935372T patent/PT1286671E/pt unknown
- 2001-05-10 CA CA2408710A patent/CA2408710C/en not_active Expired - Fee Related
- 2001-05-14 US US09/853,619 patent/US6914067B2/en not_active Expired - Fee Related
-
2003
- 2003-08-23 HK HK03106060A patent/HK1053975A1/xx not_active IP Right Cessation
-
2005
- 2005-05-11 US US11/126,315 patent/US7479499B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE322265T1 (de) | 2006-04-15 |
CA2408710A1 (en) | 2001-11-22 |
DE60118547D1 (de) | 2006-05-18 |
WO2001087306A2 (en) | 2001-11-22 |
PT1286671E (pt) | 2006-08-31 |
CA2408710C (en) | 2010-01-26 |
EP1286671A2 (en) | 2003-03-05 |
DK1286671T3 (da) | 2006-07-17 |
WO2001087306A8 (en) | 2002-10-03 |
EP1286671B1 (en) | 2006-04-05 |
DE60118547T2 (de) | 2007-02-01 |
US20020035091A1 (en) | 2002-03-21 |
NZ522766A (en) | 2005-09-30 |
AU2001261473B2 (en) | 2006-09-14 |
US6914067B2 (en) | 2005-07-05 |
ES2261415T3 (es) | 2006-11-16 |
US20050203060A1 (en) | 2005-09-15 |
JP4679028B2 (ja) | 2011-04-27 |
US7479499B2 (en) | 2009-01-20 |
JP2003533483A (ja) | 2003-11-11 |
AU6147301A (en) | 2001-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6147301A (en) | Compositions and methods for the treatment of colorectal cancer | |
MXPA02011218A (es) | Composiciones y metodos para el tratamiento de cancer. | |
IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
WO2004052280A3 (en) | Anti-angiogenic compounds and their use in cancer treatment | |
MXPA04006039A (es) | Metodo para el tratamiento de afecciones vasculares y neuronales perifericas. | |
AU4768301A (en) | Synergistic methods and compositions for treating cancer | |
HUP0400231A3 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
PL368971A1 (en) | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | |
DE60124387D1 (de) | Synergistische kombination zur behandlung von kolorektalkarzinom | |
WO2002094189A3 (en) | Compositions and methods for treating or preventing convulsions or seizures | |
PL368271A1 (en) | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine | |
WO2002039994A3 (en) | Methods for the treatment and prevention of urinary stone disease | |
UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
GB0020504D0 (en) | Therapeutic method | |
PL357179A1 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
EP1303300A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS | |
WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
WO2003014128A3 (de) | Tumorhemmende cerverbindungen | |
WO2001074341A3 (en) | Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant | |
UA43257A (uk) | Спосіб лікування критичної ішемії нижніх кінцівок | |
WO2003000182A3 (en) | Ppar-alpha ligands for the treatment or prevention of cachexia | |
IL160412A0 (en) | Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer | |
UA36251A (uk) | Спосіб комплексної терапії простої шизофренії | |
UA33545A (uk) | Спосіб лікування дакріоциститу | |
UA32314A (uk) | Спосіб лікування некротичного панкреатиту |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150510 |